1 Antisense pre-treatment increases long-lasting benefit of gene therapy in dystrophic muscles Cécile Peccate 1 , Amédée Mollard 1 , Maëva Le Hir 2 , Laura Julien 1 , Graham McClorey 3 , Susan Jarmin 4 , Anita Le Heron 4 , George Dickson 4 , Sofia Benkhelifa-Ziyyat 1 , France Piétri-Rouxel 1 , Matthew J. Wood 3 , Thomas Voit 15 and Stéphanie Lorain 1* 1 Sorbonne Universités UPMC Univ Paris 06, Inserm, CNRS, Institut de Myologie, Centre de Recherche en Myologie (CRM), GH Pitié Salpêtrière, 105 bd de l'Hôpital, Paris 13, France. 2 Université de Versailles St-Quentin, INSERM U1179, LIA BAHN CSM, Montigny-le- Bretonneux, France. 3 Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford, OX1 3QX, UK. 4 School of Biological Sciences, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK. 5 New address: NIHR Biomedical Research Centre, Institute of Child Health, University College London, 30 Guilford Street, London, WC1N 1EH, UK. * Correspondence should be addressed to SL (stephanie.lorain@upmc.fr) Combined treatment for Duchenne muscular dystrophy AAV vector / Duchenne muscular dystrophy / Exon skipping / Gene therapy